Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents
- 11 June 2010
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (1) , 102-108
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Adverse drug reactions (ADRs) are a reporting category in the National Patient Safety Agency (NPSA) incident reporting system, though the Medicines and Healthcare Products Regulatory Agency (MHRA) pharmacovigilance system is the more established method for collecting ADR data. WHAT THIS STUDY ADDS • The majority of ADRs were shown to be of moderate risk to the patient, though some have a severe or catastrophic impact. Classification and reporting of ADRs according to NPSA guidance is possible but offers limited additional value to efforts to improve patient safety over and above the Yellow Card Scheme.AIM: In the UK, the National Patient Safety Agency (NPSA) includes adverse drug reactions as a reporting category, while the MHRA Yellow Card Scheme also collects data regarding adverse drug reactions (ADRs). In this study, we aimed to assess ADRs using NPSA criteria and discuss the resulting implications.METHODS: ADRs identified in a 6‐month prospective study of 3695 inpatient episodes were assessed according to their impact on the patient and on the organization, using tools developed by the NPSA.RESULTS: Seven hundred and thirty‐three (100%) ADRs were assessed. In terms of impact on the patient, 537 (73.3%) were categorized as ‘low’ (minor treatment), 181 (24.7%) as ‘moderate’ (moderate increase in treatment, no permanent harm), 14 (1.91%) as ‘severe’ (permanent harm) and 1 (0.14%) was categorized as ‘catastrophic’ (direct cause of death). In terms of impact on the organization, none was categorized as ‘no harm/ no risk’, 508 (69.3%) as ‘insignificant’, 188 (25.6%) as ‘minor’, 25 (3.4%) as ‘moderate’, 12 (1.6%) as ‘major’ and none was classed as ‘catastrophic’. Less than 2% of ADRs would be eligible for detailed analysis according to the NPSA guidance. The ADRs that cause incidents of greater significance relate to bleeding, renal impairment and Clostridium difficile infection.CONCLUSIONS: Classification of ADRs according to NPSA guidance offers limited additional value over and above that offered by the Yellow Card System. A consistent message needs to be sent to prospective reporters of ADRs; the availability of more than one system is likely to confuse reporters and does not aid patient safety.Keywords
This publication has 16 references indexed in Scilit:
- Medication errors: definitions and classificationBritish Journal of Clinical Pharmacology, 2009
- Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-EpisodesPLOS ONE, 2009
- Adverse drug reactions in hospital in-patients: a pilot studyJournal of Clinical Pharmacy and Therapeutics, 2006
- What can hospitalized patients tell us about adverse events? Learning from patient-reported incidentsJournal of General Internal Medicine, 2005
- The JCAHO patient safety event taxonomy: a standardized terminology and classification schema for near misses and adverse eventsInternational Journal for Quality in Health Care, 2005
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- National Patient Safety Agency: an introductionClinical Governance: An International Journal, 2004
- Achieving consistency in grading adverse clinical incidents: does Doing Less Harm do the job?British Journal of Clinical Governance, 2002
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000
- Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of preventionJournal of Internal Medicine, 1990